CM Life Sciences III Inc. (CMLTU)
Price:
8.87 USD
( - -0.62 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
CM Life Sciences III Inc. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.
NEWS
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
businesswire.com
2021-09-13 20:40:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of updated data from its partner CStone Pharmaceuticals' Phase 3 GEMSTONE-302 study at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer (IASLC 2021 WCLC). GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III
businesswire.com
2021-08-06 07:00:00CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. The transaction is expe
CM Life Sciences III Inc. Announces Separate Trading of Its Shares of Class A Common Stock and Warrants, on or About May 28, 2021
businesswire.com
2021-05-26 16:15:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (Nasdaq: CMLTU) (the “Company”) today announced that holders of the Company's units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about May 28, 2021. The shares of Class A common stock and warrants that are separated will trade on The Nasdaq Capital Market (“Nasdaq”) under the symbols “CMLT” and “CMLTW,” respectively. Those un
Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and more
geekwire.com
2021-04-15 15:55:19— Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC.
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
seekingalpha.com
2021-04-11 14:17:12Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week.
CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering
businesswire.com
2021-04-09 16:20:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (the “Company”) announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued pursuant to the exercise in full by the underwriters of its over-allotment option. The units are listed on The Nasdaq Capital Market (“Nasdaq”) and began trading under the ticker symbol “CMLTU” on April 7, 2021. Each unit consists of one share of Class A common stock and one-fifth of one redeemabl
No data to display
No data to display
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
businesswire.com
2021-09-13 20:40:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of updated data from its partner CStone Pharmaceuticals' Phase 3 GEMSTONE-302 study at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer (IASLC 2021 WCLC). GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III
businesswire.com
2021-08-06 07:00:00CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. The transaction is expe
CM Life Sciences III Inc. Announces Separate Trading of Its Shares of Class A Common Stock and Warrants, on or About May 28, 2021
businesswire.com
2021-05-26 16:15:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (Nasdaq: CMLTU) (the “Company”) today announced that holders of the Company's units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about May 28, 2021. The shares of Class A common stock and warrants that are separated will trade on The Nasdaq Capital Market (“Nasdaq”) under the symbols “CMLT” and “CMLTW,” respectively. Those un
Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and more
geekwire.com
2021-04-15 15:55:19— Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC.
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
seekingalpha.com
2021-04-11 14:17:12Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week.
CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering
businesswire.com
2021-04-09 16:20:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (the “Company”) announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued pursuant to the exercise in full by the underwriters of its over-allotment option. The units are listed on The Nasdaq Capital Market (“Nasdaq”) and began trading under the ticker symbol “CMLTU” on April 7, 2021. Each unit consists of one share of Class A common stock and one-fifth of one redeemabl